Spyre Therapeutics, Inc.

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece

Soon-to-be public Oruka Therapeutics will execute a reverse merger with ARCA Biopharma, Inc. and a concurrent $275m financing to help it start clinical development of optimized biologics in psoria

Pfizer Inc. held a 32% stake in Haleon plc after the consumer health business spun out of GSK plc in 2022, but through a sale of stock on 19 March Pfizer reduced its stake to 22.6% and garnered $